Journals / Turkish Journal of Gastroenterology / 2015 / Cilt: 26 - Sayı: 3

Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis

Pages
244–250
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Keywords: Mesenchymal stem cells transplantation, liver cirrhosis, liver biopsy

📌 3 Key Takeaways

🎯
Objective & Hypothesis:ABSTRACT Background/Aims: Because of several limitations and complications of liver transplantation, new alternative treat- ment modalities are required for patients with liver cirrhosis.
📊
Key Findings & Data:Pa- tients received 1×106 autologous mesenchymal stem cells/kg via a peripheral vein.
💡
Conclusion & Impact:Keywords: Mesenchymal stem cells transplantation, liver cirrhosis, liver biopsy
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

ABSTRACT Background/Aims: Because of several limitations and complications of liver transplantation, new alternative treat- ment modalities are required for patients with liver cirrhosis. Many study results encourage the use of autologous bone marrow-derived mesenchymal stem cells for liver diseases. In this study, we assessed the impact of autolo- gous mesenchymal stem cell transplantation on liver tissue and liver chemistry. Materials and Methods: Twenty-five patients with biopsy-proven liver cirrhosis were enrolled in the study. Pa- tients received 1×106 autologous mesenchymal stem cells/kg via a peripheral vein. Biochemical parameters were checked monthly. Periodical radiological screening and liver biopsies before mesenchymal stem cell transplanta- tion were performed after 6 months. Liver specimens were assessed by a pathologist. Results: No side effect was observed and the mesenchymal stem cell transplantation procedure was well tol- erated. Twelve patients completed the study. In 8 patients, improvements in Model for End-Stage Liver Disease (MELD) scores were observed. Serum albumin levels markedly increased in the third month. In patients with non- responder hepatitis C, HCV RNA levels both became negative after mesenchymal stem cell transplantation. Histo- pathological examinations of liver tissues before and at 6 months after transplantation revealed no change in liver tissue regeneration or fibrosis. However, in 5 patients, hepatitis activity index scores decreased. Conclusion: Autologous mesenchymal stem cell transplantation via peripheral vein is safe and feasible. Consecu- tive liver biopsy examinations suggested that mesenchymal stem cells could not reach the liver in a sufficient amount. Improvement in patients and clearance of HCV RNA may have occurred through immunomodulatory mediators secreted by transplanted mesenchymal stem cells, namely the endocrine effect. Keywords: Mesenchymal stem cells transplantation, liver cirrhosis, liver biopsy

🔖

Cite This Article

KANTARCIOĞLU, M., DEMİRCİ, H., AVCU, F., KARSLIOĞLU, Y., BABAYİĞİT, M. A., KARAMAN, B., ÖZTÜRK, K., GUREL, H., KAYHAN, M. A., KACAR, S., KUBAR, A., ÖKSÜZOĞLU, G., URAL, A. U., BAĞCI, S. (2015). Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis. Turkish Journal of Gastroenterology, Cilt: 26 - Sayı: 3, 244–250. https://ajindex.com/articles/409386

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil RW. Major challenges limiting liver transplantation in the United States. Am J Transplant 2011
  2. [CrossRef] 2. Pan Q, Fouraschen SM, Kaya FS, et al. Mobilization of hepatic mesenchymal stem cells from human liver grafts. Liver Transplan 2011
  3. [CrossRef] 3. Kuwahara R, Kofman AV, Landis CS, Swenson ES, Barendswaard E, Theise ND. The Hepatic Stem Cell Niche: Identification by Label- Retaining Cell Assay. Hepatology 2008
  4. [CrossRef] 4. Alison MR, Lin WR. Hepatocyte turnover and regeneration: virtually a virtuoso performance. Hepatology 2011
  5. [CrossRef] 5. Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capac- ity, immunological features, and potential for homing. Stem Cells 2007
  6. [CrossRef] 6. Petersen BE, Bowen WC, Patrene KD, et al. Bone Marrow as a potential source of hepatic oval cells. Science 1999
  7. [CrossRef] 7. Alison MR, Poulsom R, Jeffery R, et al. Hepatocytes from non-he- patic adult stem cells. Nature 2000
  8. [CrossRef] 8. Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lin- eage engraftment by a single bm-derived stem cell. Cell 2001
  9. [CrossRef] 9. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone mar- row cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004
  10. [CrossRef] 10. Terai S, Ishikawa T, Omori K, et al. Improved liver function in liver cirrhosis patients after autologous bone marrow cell infusion therapy. Stem Cells 2006
  11. [CrossRef] 11. Kharaziha P, Hellstrom PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesen- chymal stem cell injection: a phase I-II clinical trial. Eur J Gastroen- terol Hepatol 2009
  12. [CrossRef] 12. Margini C, Vukotic R, Brodosi L, Bernardi M, Andreone P. Bone marrow derived stem cells for the treatment of end-stage liver disease. World J Gastroenterol 2014
  13. Bosse R, Kulmburg P, Von Kalle C, et al. Production of stem-cell transplants according to good manufacturing practice. Ann He- matol 2000
  14. [CrossRef] 14. Sener K, Yapar M, Bedir O, Gül C, Coskun O, Kubar A. Stability of Hepatitis C Virus RNA in Blood Samples by TaqMan Real-Time PCR. J Clin Lab Anal 2010
  15. [CrossRef] 15. Zhong YS, Lin N, Deng MH, Zhang FC, Tang ZF, X